Antibodies against oxLDL and acute coronary syndrome;Anticorpos contra LDL-ox e síndrome coronariana aguda

Arquivos Brasileiros de Cardiologia

Volumn 95, Issue 1, 2010, Pages 47-54

  Medeiros, Ana Maria Brito ^a   Von Mühlen, Carlos Alberto ^a   Gidlund, Magnus Ake ^b   Bodanese, Rodrigo ^a   Gottlieb, Maria G V ^a   Bodanese, Luiz C ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Acute coronary syndrome; Autoantibodies; LDL; Lipoproteins

Indexed keywords

ANTIBODY; ANTIPEPTD; APOLIPOPROTEIN B; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTIBODY TITER; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHRONIC DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; SMOKING; STATISTICAL SIGNIFICANCE;

ACUTE CORONARY SYNDROME; ACUTE DISEASE; ADULT; AGED; APOLIPOPROTEINS B; AUTOANTIBODIES; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; RISK FACTORS;

EID: 77956862525     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2010005000063     Document Type: Article

References (39)

1. Itabe H. Oxidative modification of LDL: its pathological role in atherosclerosis. Clin Rev Allergy Immunol. 2009; 37 (1): 4-11. [Links]
2. Steinberg D, Witztum JL. Lipoproteins and atherogenesis: current concepts. JAMA. 1990; 264: 3047-52. [Links]
3. Gounopoulos P, Merki E, Hansen LF, Choi SH, Tsimikas S. Antibodies to oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease. Minerva Cardioangiol. 2007; 55 (6): 821-37. [Links]
4. Xavier HT, Abdalla DSP, Martinez TLR, Ramires JAF, Gagliardi ART. Efeitos da lipoproteína LDL-oxidada sobre a proliferação e a motilidade espontânea in vitro de células endoteliais de artérias coronárias humanas. Arq Bras Cardiol. 2004; 63: 488-92. [Links]
5. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony - stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol. 2001; 158 (3): 879-91. [Links] (Pubitemid 32221781)
6. Chou MY, Hartvigsen K, Hansen LF, Fogelstrand L, Shaw PX, Boullier A, et al. Oxidation-specific epitopes are important targets of innate immunity. J Intern Med. 2008; 263 (5): 479-88. [Links] (Pubitemid 351533561)
7. Soltesz P, Veres K, Laczik R, Der H, Csipo I, Timar O, et al. Evaluation of antibodies to oxidized low-density lipoprotein and assessment of C-reactive protein in acute coronary syndrome and stable coronary artery disease. Thromb Haemost. 2007; 98 (2): 413-9. [Links] (Pubitemid 47250245)
8. Rossi GP, Cesari M, De Toni R, Zanchetta M, Maiolino G, Pedon L, et al. Antibodies to oxidized low-density lipoproteins and angiographically assessed coronary artery disease in White patients. Circulation. 2003; 108: 2467-72. [Links] (Pubitemid 37444407)
9. Braunwald E. Unstable angina: a classification. Circulation. 1989; 80: 410-4. [Links]
10. Campeau L. Grading of angina pectoris [letter]. Circulation. 1976; 54: 522-3. [Links]
11. Lowry OH, Rosebbough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951; 193 (1): 265-75. [Links]
12. Harada LM, Carvalho MD, Passarelli M, Quintão EC. Lipoprotein desialylation simoltaneously enhances the cell cholesterol uptake and impairs the reverse cholesterol transport system: in vitro evidences utilizing neuraminidase-treated lipoproteins and mouse peritoneal macrophages. Atherosclerosis. 1998; 139: 65-75. [Links] (Pubitemid 28341868)
13. Gidlund MA, Damasceno NR, Lindoso JA, Abdalla DS, Goto H. Monoclonal antibodies against low density lipoprotein with various degrees of oxidative modifications. Braz J Med Biol Res. 1996; 29: 1625-8. [Links] (Pubitemid 126485411)
14. Magalhães CK, Siqueira Filho AG, Amino JGOC, Nolasco M. Correlação entre marcadores bioquímicos e a cineangiocoronariografia em portadores de síndromes isquêmicas agudas sem supradesnivelamento de segmento ST. Arq Bras Cardiol. 2006; 86: 223-31. [Links]
15. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patients: a call for new definitions and risk assessment strategies: part I. Circulation. 2003; 108: 1664-72. [Links]
16. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease, JAMA. 2003; 290: 898-904. [Links]
17. Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis. 1996; 124: S1-S9. [Links]
18. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347: 1557-65. [Links] (Pubitemid 35315836)
19. Ammirati E, Vermi AC, Cianflone D, Banfi M, Foglieni C, Godino C, et al. Expansion of T-Cell receptor zeta dim effector T cells in acute coronary syndromes. Arterioscler Thromb Vasc Biol. 2008; 28 (12): 2305-11. [Links]
20. Ehara S, Ueda M, Nakuro T, Haze K, Itoh A, Otsuka M, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001; 103: 1955-60. [Links] (Pubitemid 32322222)
21. Tsimikas S, Beyer RW, Patel R, Miller E, Juliano J, Wilztum JL. Prospective evaluation of the role of oxidized LDL in acute coronary syndromes treated with percutaneous intervention. Circulation. 2000; 102: II-13. [Links]
22. Tsimikas S, Witztum JL. Measuring circulating oxidized low-density lipoprotein to evaluate coronary risk. Circulation. 2001; 103: 1930-2. [Links] (Pubitemid 32322217)
23. Holvoet P, Lee DH, Steffes M, Gross M, Jacobs DR Jr. Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA. 2008; 299 (19): 2287-93. [Links] (Pubitemid 351724395)
24. Palinski W, Witztum JL. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med. 2000; 247: 371-80. [Links] (Pubitemid 30180039)
25. Shaw PX, Horkko S, Tsimikas S, Chang M, Palinski W, Silverman G, et al. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesion in vivo. Arterioscler Thromb Vasc Biol. 2001; 21: 1333-9. [Links] (Pubitemid 34219841)
26. Shoenfeld Y, Harats D, George J. Heat shock protein 60/65, beta 2-glycoprotein I and oxidized LDL as players in murine atherosclerosis. J Autoimmun. 2000; 15: 199-202. [Links]
27. Napoli C, Glass CK, Witztum JL, Deutsch R, D'Armiento FP, Palinski W. Influence of maternal hypercholesterolemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet. 1999; 354: 1234-41. [Links] (Pubitemid 29469351)
28. Virella G, Lopes-Virella MF. Lipoprotein autoantibodies: measurement and significance. Clin Diagn Lab Immunol. 2003; 10: 499-505. [Links]
29. Mangueira CLP. Autoantibodies against copper-oxidized low density lipoprotein, apolipoprotein-B derived peptides and cardiolipin in rheumatoid arthritis patients: correlation with disease activity and other clinical parameters [tese]. São Paulo (SP): Faculdade de Medicina . Universidade de São Paulo; 2003. [Links]
30. Tornvall P, Waeg G, Nilsson J, Hamsten A, Regnström J. Autoantibodies against low-density lipoproteins in coronary artery disease. Atherosclerosis. 2003; 167: 347-53. [Links] (Pubitemid 36773534)
31. Doo YC, Han SJ, Lee JH, Cho GY, Hong KS, Han KR, et al. Associations among oxidized low-density lipoprotein antibody, C-reactive protein, interleukin-6, and circulating cell adhesion molecules in patients with unstable angina pectoris. Am J Cardiol. 2004; 93: 554-8. [Links]
32. Libby P. Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis and stabilization. Am J Cardiol. 2000; 86: 3-8. [Links]
33. Itabe H, Yamamoto H, Imanaka T, Shimamura k, Uchiyama H, Kimura J, et al. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res. 1996; 37: 45-53. [Links]
34. Dotevall A, Hulthe J, Rosengren A, Wiklund O, Wilhelmsen L. Autoantibodies against low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women. Clin Sci. 2001; 101: 523-31. [Links] (Pubitemid 33032997)
35. Awadallah SM, Hamad M, Jbarah I, Salem NM, Mubarak MS. Autoantibodies against oxidized LDL correlate with serum concentrations of ceruloplasmin in patients with cardiovascular disease. Clin Chim Acta. 2006; 365 (1-2): 330-6. [Links] (Pubitemid 43196456)
36. Fagerberg B, Bokemark L, Hulthe J. The metabolic syndrome, smoking, and antibodies to oxidized LDL in 58-year-old clinically heath men. Nutr Metab Cardiovasc Dis. 2001; 4: 217-20. [Links] (Pubitemid 33686212)
37. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003; 107: 363-9. [Links]
38. Ridker PM, Danielson E, Fonseca F, Genest J, Gotto AM Jr, Kastelein JJ, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359 (21): 2195-207. [Links]
39. Holvoet P, Collen D, Van de Wert F. Malondialdehyde-modified LDL as a marker of acute coronary syndromes. JAMA. 1999; 281: 1718-21. [Links] (Pubitemid 29226482)